MicroRNA targeted therapy for overcoming drug resistance, reversal of EMT and elimination of cancer stem cells in prostate and pancreatic cancer

MicroRNA Targeted Cancer Therapy

Volumn , Issue , 2014, Pages 199-217

  Li, Yiwei ^a   Kong, Dejuan ^a   Ahmad, Aamir ^a   Bao, Bin ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930063444     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-05134-5_12     Document Type: Chapter

References (61)

1. Gangaraju VK, Lin H (2009) MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 10:116-125
2. Hwang HW, Mendell JT (2007) MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 96(Suppl):R40-R44
3. Bao B, Ahmad A, Azmi AS .et al. (2013) Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol Chapter 14: Unit. doi:10.1002/0471141755.ph1425s61
4. Hotz HG, Hotz B, Buhr HJ (2011) Genes associated with epithelial-mesenchymal transition: possible therapeutic targets in ductal pancreatic adenocarcinoma? Anticancer Agents Med Chem 11:448-454
5. Ni X, Long J, Cen P .et al. (2012) Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. J Cell Mol Med 16:988-994
6. Bhat K, Wang F, Ma Q .et al. (2012) Advances in biomarker research for pancreatic cancer. Curr Pharm Des 18:2439-2451
7. Hamada S, Satoh K, FujibuchiW.et al. (2012) MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 10:3-10
8. Tang S, Bonaroti J, Unlu S .et al. (2013) Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas 42:740-759
9. Wang J, Chen J, Chang P .et al. (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2:807-813
10. Yabushita S, Fukamachi K, Tanaka H .et al. (2012) Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas 41: 1013-1018
11. Nagathihalli NS, Nagaraju G (2011) RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta 1816:209-218
12. Bryant JL, Britson J, Balko JM .et al. (2012) A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 106:148-156
13. Bhutia YD, Hung SW, Krentz M .et al. (2013) Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. PLoS One 8:e53436
14. Tan L, Sui X, Deng H .et al. (2011) Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One 6: e23383
15. Li Y, VandenBoom TG, Kong D .et al. (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69:6704-6712
16. Wellner U, Schubert J, Burk UC .et al. (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487-1495
17. Burk U, Schubert J, Wellner U .et al. (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9: 582-589
18. Sureban SM, May R, Lightfoot SA .et al. (2011) DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 71:2328-2338
19. Bao B, Wang Z, Ali S .et al. (2011) Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 112: 2296-2306
20. Bao B, Wang Z, Ali S .et al. (2011) Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307:26-36
21. Brabletz S, Bajdak K, Meidhof S .et al. (2011) The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 30:770-782
22. Bao B, Ali S, Ahmad A .et al. (2012) Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 7:e50165
23. Kent OA, Mullendore M, Wentzel EA .et al. (2009) A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 8: 2013-2024
24. Nalls D, Tang SN, Rodova M .et al. (2011) Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6: e24099
25. Ji Q, Hao X, Zhang M .et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4:e6816
26. Harazono Y, Muramatsu T, Endo H .et al. (2013) miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One 8:e62757
27. Hamada S, Satoh K, Miura S .et al. (2013) miR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cell Physiol 228:1255-1263
28. Jung DE, Wen J, Oh T .et al. (2011) Differentially expressed microRNAs in pancreatic cancer stem cells. Pancreas 40:1180-1187
29. Peng X, Guo W, Liu T .et al. (2011) Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6:e20341
30. Kojima K, Fujita Y, Nozawa Y .et al. (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70:1501-1512
31. Lucotti S, Rainaldi G, Evangelista M .et al. (2013) Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival. Mol Cancer 12:52
32. Shi GH, Ye DW, Yao XD .et al. (2010) Involvement of microRNA-21 in mediating chemoresistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 31:867-873
33. Cao Q, Mani RS, Ateeq B .et al. (2011) Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20:187-199
34. Li X, Chen YT, Josson S .et al. (2013) MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One 8:e70987
35. Kong D, Banerjee S, Ahmad A .et al. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5:e12445
36. Singh S, Chitkara D, Mehrazin R .et al. (2012) Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One 7:e40021
37. Liu C, Kelnar K, Liu B .et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17:211-215
38. Hsieh IS, Chang KC, Tsai YT .et al. (2013) MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 34:530-538
39. Saini S, Majid S, Shahryari V .et al. (2012) miRNA-708 control of CD44(+) prostate cancerinitiating cells. Cancer Res 72:3618-3630
40. Li K, Liu C, Zhou B .et al. (2013) Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci 14:11981-11993
41. Liu YN, Yin JJ, Abou-Kheir W .et al. (2013) MiR-1 and miR-200 inhibit EMT via Slugdependent and tumorigenesis via Slug-independent mechanisms. Oncogene 32:296-306
42. Coppola V, Musumeci M, Patrizii M .et al. (2013) BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene 32:1843-1853
43. Kong D, Li Y, Wang Z .et al. (2009) miR-200 regulates PDGF-D-mediated epithelialmesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27: 1712-1721
44. Tucci P, Agostini M, Grespi F .et al. (2012) Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A 109: 15312-15317
45. Bao B, Ahmad A, Kong D .et al. (2012) Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 7:e43726
46. Majid S, Dar AA, Saini S .et al. (2012) miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res 72:6435-6446
47. Gupta PB, Onder TT, Jiang G .et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645-659
48. Zhang GN, Liang Y, Zhou LJ .et al. (2011) Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett 313:137-144
49. Kong D, Heath E, Chen W .et al. (2012) Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res 4:14-23
50. Kong D, Heath E, Chen W .et al. (2012) Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 7:e33729
51. Bao B, Ali S, Kong D .et al. (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6:e17850
52. Bao B, Ali S, Banerjee S .et al. (2012) Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72:335-345
53. Ali S, Ahmad A, Banerjee S .et al. (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70:3606-3617
54. Soubani O, Ali AS, Logna F .et al. (2012) Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 33:1563-1571
55. Bao B, Wang Z, Ali S .et al. (2012) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 5:355-364
56. Babar IA, Cheng CJ, Booth CJ .et al. (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 109:E1695-E1704
57. Sureban SM, May R, Mondalek FG .et al. (2011) Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnol 9:40
58. Krutzfeldt J, Rajewsky N, Braich R .et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689
59. Pramanik D, Campbell NR, Karikari C .et al. (2011) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10:1470-1480
60. Liguori L, Falanga A .et al. (2013) MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol 386:287-302
61. Wu X, Ding B, Gao J .et al. (2011) Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine 6:1747-1756